Studies have shown that ATO inhibits the nuclear factor (NF)-κB signaling pathway in leukemia cells and hepatocellular carcinoma stem cells by downregulating expression of p65, p50, p52, P65, c-rel, and RELB members of the NF-κB pathway [159,160]. This evidence concerns the gene NFKB1 and leukemia.